Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 41.87 -0.74 (-1.74%) Market Cap: 3.48 Bil Enterprise Value: 3.11 Bil PE Ratio: 0 PB Ratio: 24.80 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 16, 2022 / 05:00PM GMT
Release Date Price: $50.02 (-1.36%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thank you, everyone, for joining us. Really pleased to have the Ultragenyx team here with us. We have Emil Kakkis, Founder, President and CEO; and Mardi Dier, CFO.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, Emil, data sets that are going to start to appear in the second half onwards, let's start with the Angelman program. As we look to that midyear efficacy and safety data update from the Phase I/II study, can you remind us of the metrics that will be considered, the number of patients we'll see data on? And what you would interpret as a positive signal for the program?

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director

Sure. So we'll be releasing data on Cohort 4, which is less than 8 group; and Cohort 5, probably the majority of patients. We will have -- the hope is to get the majority of patient Day 128 data. And what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot